PHR Pharmena S.A.

0.6737USD2.710 PLN · GPW0.00%Mkt Cap: 7.50M USDP/E: —

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved…

Key Statistics

Company
Market Cap7.50M USD
Enterprise Value7.48M USD
Revenue (TTM)363.21K USD
Gross Profit326.42K USD
Net Income (TTM)-688.39K USD
Revenue/Share0.03 USD
Last Price0.6737 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLPHRMN00011
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-9.10
EV/Revenue20.59
P/S20.66
P/B3.69
EPS (TTM)-0.07 USD
EPS (Forward)—
52W Range
0.621512% of range1.074
52W High1.074 USD
52W Low0.6215 USD
Profitability
Gross Margin83.26%
Oper. Margin-228.61%
EBITDA Margin-226.15%
Profit Margin-175.59%
ROE-28.70%
ROA-25.35%
ROIC-143.15%
ROCE-32.91%
Growth
Revenue Growth-37.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-817.91K USD
CapEx (TTM)1.89M USD
FCF Margin85.29%
FCF Yield4.13%
Net Debt-26.60K USD
Net Debt/EBITDA0.03
Net Debt/FCF-0.09
Balance Sheet
Debt/Equity0.04
Current Ratio6.69
Quick Ratio0.99
Book Value/Sh0.18 USD
Cash/Share0.0094 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield0.58%
Payout Ratio0.00%
Ex-Div DateApr 9, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.14M
Float3.31M
Insiders70.30%
Institutions1.86%
Technical
SMA 500.7446 (-9.5%)
SMA 2000.7961 (-15.4%)
Beta0.48
S&P 52W Chg12.00%
Avg Vol (30d)2.08K
Avg Vol (10d)1.93K
Technical Indicators
RSI (14)33.7
MACD-0.1081
MACD Signal-0.0920
MACD Hist.-0.0162
BB Upper0.7895 USD
BB Middle0.7229 USD
BB Lower0.6564 USD
BB Width18.41%
ATR (14)0.0263 USD
Vol Ratio (20d)1.96x

About Pharmena (WSE: PHR)

›

Pharmena (WSE: PHR) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.

The shares were at 2.710 PLN on 19 November 2026, down 21.4% over 52 weeks. Its 52-week range is 2.500 PLN to 4.320 PLN: the price is 37.3% below the high and 8.4% above the low.

Its market capitalisation is 30.18M PLN.

Pharmena reports return on equity of -28.7%, an operating margin of -228.6% and revenue down 37.3% year over year.

It holds more cash than debt, a net cash position of 107.00K PLN. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.